

• **Name:** Jeong Eun Kim

• **Current Position:**

Clinical Associate Professor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine

• **Country:** South Korea

• **Educational Background:**

1999. 3 – 2005. 2	M.D. College of Medicine Pusan National University Busan, Korea
2008. 3 – 2010. 2	Master University of Ulsan College of Medicine Seoul, Korea
2010. 3 – 2012. 2	Ph. D. University of Ulsan College of Medicine Seoul, Korea

• **Professional Experience:**

2005. 3 – 2006.2	Internship Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2006.3 – 2010. 2	Residency, Internal Medicine Asan Medical Center University of Ulsan College of Medicine Seoul, Korea
2010.3 – 2012.2	Clinical fellow Department of Oncology

Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

2012.3 –2015.2 Clinical Instructor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

2015.3 – Clinical Assistant Professor
Department of Oncology
Asan Medical Center
University of Ulsan College of Medicine
Seoul, Korea

• **Professional Organizations:**

Member, Korean Medical Association
Member, Korean Society of Internal Medicine
Member, Korean Cancer Study Group
Member, Korean Cancer Association
Member, Korean Society of Hematology
Member, Korean Association for Clinical Oncology
Member, American Society of Clinical Oncology
Member, Multinational Association of Supportive Care in Cancer

• **Main Scientific Publications:**

1. Kim JH, **Kim JE** et al. Increased incidence of chemoport-related thrombosis in patients with colorectal cancer receiving bevacizumab. Chinese Journal of Cancer Research 2018;30(4):460-467
2. **Kim JE**, Chun SM, Kim TW et al. Mutation burden and I index for Detection of microsatellite instability in colorectal cancer by targeted next-generation sequencing. Journal of Molecular Diagnostics. 2019 Mar;21(2):241-250
3. Moon JH, Hong SW, **Kim JE** et al. Targeting β -catenin overcomes MEK inhibition resistance in colon cancer with *KRAS* and *PIK3CA* mutations. British journal of Cancer. 2019.120,941-951
4. **Kim JE**, Chae SY, Kim JH et al. 3'-Deoxy-3'-18F-Fluorothymidine and 18F-Fluorodeoxyglucose positron emission tomography for the early prediction of response to Regorafenib in patients with metastatic colorectal cancer refractory to all standard therapies. European Journal of Nuclear Medicine and

Molecular Imaging. 2019 [Epub ahead of print]

5. Chae SY, Kim SB, **Kim JE** et al. Diagnostic accuracy and safety of $^{16}\alpha$ -[^{18}F]fluoro- $^{17}\beta$ -oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. *Lancet Oncology*. 2019 May;20:4
6. **Kim JE**, Kim DH, Hong YS et al. Mutation profiling of malignant mesothelioma revealed potential therapeutic targets in EGFR and NRAS. *Translational Oncology* 2018 11, 268-274
7. Kim JJ, Kang JH, **Kim JE** et al. Oxaliplatin rechallenge in metastatic colorectal cancer patients after prior oxaliplatin treatment. *Medical Oncology* 2018 May 35:65
8. Kim SY, Joo J, Kim TW, Hong YS, **Kim JE** et al. A Randomized Phase 2 Trial of Consolidation Chemotherapy After Preoperative Chemoradiation Therapy Versus Chemoradiation Therapy Alone for Locally Advanced Rectal Cancer: KCSG CO 14-03. *Int J Radiat Oncol Biol Phys* 2018 Jul 15;101(4):889-899
9. Oh CR, **Kim JE**, Kang JH et al. Prognostic value of the microsatellite instability status in stage II/III rectal cancer patients following upfront surgery. *Clinical Colorectal Cancer* 2018 Dec;17(4):e679-685
10. **Kim JE**, Jang JS, Kim JW et al. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. *Support Care Cancer*. 2017 Mar;25(3):801-809
11. **Kim JE**, Hong YS et al. Microsatellite Instability was not Associated with Survival in Stage III Colon Cancer Treated with Adjuvant Chemotherapy of Oxaliplatin and Infusional 5-Fluorouracil and Leucovorin (FOLFOX). *Ann Surg Oncol*. 2017 May;24(5):1289-1294
12. Balliger ML, Goode DL, **Kim JE** et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. *Lancet Oncol*: 17(9):1261-71, 2016